Lead Product(s) : Oxybutynin,Lidocaine
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.
Product Name : TRG-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2021
Lead Product(s) : Oxybutynin,Lidocaine
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable